This was confirmed Monday in a message on the social network X from the Ministry of Science, Technology and Environment of Cuba.

In the text, it is pointed out that “Heberprot-P will be among the first medicines to arrive in the United Arab Emirates, following recent agreements on the commercialization of Cuban biotechnology products”. Intended for the treatment of patients with diabetic foot ulcers in advanced stages, this drug is the only one in the world capable of stimulating accelerated granulation and re-epithelialization in diabetic foot ulcers and reduces the healing time of these lesions, thus reducing the number of debridements and the risk of amputation.

Cuban scientists have pointed out on several occasions that the effectiveness of Heberprot-P has been demonstrated for more than 20 years and some 26 countries have registered it, which has favored the quality of life of almost 450,000 people.

jrr/jav/ro/cdg